Good expectaions by Seetrhoughequity again here...
Post# of 128
Posted On: 11/03/2014 10:02:05 AM
Re: rustydog62 #20
Good expectaions by Seetrhoughequity again here...
Manhattan Scientifics mentioned in this article. Huge Growth Delivered in Very Small Packages: SeeThruEquity’s Ajay Tandon and Brandon Primack
TLSR: Could we talk about other companies?
BP: Manhattan Scientifics Inc. (MHTX:OTCMKTS) is a good segue to your question about the costs of personalized therapies. One way to lower costs is with better detection methods. Manhattan Scientifics is developing magnetic relaxometry (MRX) technology, which uses iron oxide nanoparticles that can be programmed to bind to specific cancer cells. Low-strength magnetic sensors are used to detect these cancer cells at an incredibly sensitive level.
Manhattan Scientifics has placed one of its MRX machines at the University of Texas MD Anderson Cancer Center, which recently presented unpublished data at the World Molecular Imaging Conference in Seoul, South Korea, that showed the technology to be up to 200 times more sensitive than current imaging technologies. We believe the technology will prove far more sensitive than that. We believe the MRX technology will lead to earlier detection, fewer false positives, fewer PET and CT scans, fewer biopsies and fewer unnecessary surgeries. We believe something like this technology could be a huge cost-fighting mechanism in the battle against cancer. The collaboration with MD Anderson will generate a lot of data over the next 12–18 months, as the technology progresses through animal trials and, hopefully, moves into human clinical trials.
Additionally, the technology could be a wonderful low-cost tool to track the progression of cancer. For instance, if you’re a prostate cancer patient, you would be able to go to your physician every three to six months and see how quickly your tumor is growing, just by taking the nanoparticles and using the sensor. This could be a tremendous cost-saver. We have a $0.25/share price target on Manhattan, and it’s currently trading around $0.12/share.
TLSR: What is the regulatory pathway for this device? Will it be a 510(k) premarket notification, or will it be a premarket approval application, like a new drug application? Or do we know?
BP: We do not know at this point. But since these nanoparticles, which pass through patients like a multivitamin, are used in other medical devices, it’s not a revolutionary technology. We do not anticipate a long, onerous process. I would anticipate the 510(k).
TLSR: Will data be emanating from the human trials when they begin at MD Anderson? Will these data act as catalysts for the stock?
BP: Manhattan is a dual thesis play. Its nanotechnology platform is also being applied to structured metals. The company has a deal with Carpenter Technology Corp. (CRS:NYSE) in nanostructured titanium. The near-term catalyst for the stock is the development of this project, which should generate sufficient revenue to carry the company to its longer-term thesis, which is the development of the MRX technology.
At this point, it’s difficult to say what the timeline might be for hearing additional news. We would love to see some major guidance on when the human trials might begin next year, but again, we don’t know at this point.
TLSR: I’m noting that Senior Scientific LLC is the MRX subsidiary of Manhattan Scientifics. Is Senior Scientific a candidate for spinout?
BP: I don’t believe so. The company has not talked about that at all. Manhattan’s two businesses have a lot of interrelated pieces within nanotechnology.
Thanks Sparrow for article...
Manhattan Scientifics mentioned in this article. Huge Growth Delivered in Very Small Packages: SeeThruEquity’s Ajay Tandon and Brandon Primack
TLSR: Could we talk about other companies?
BP: Manhattan Scientifics Inc. (MHTX:OTCMKTS) is a good segue to your question about the costs of personalized therapies. One way to lower costs is with better detection methods. Manhattan Scientifics is developing magnetic relaxometry (MRX) technology, which uses iron oxide nanoparticles that can be programmed to bind to specific cancer cells. Low-strength magnetic sensors are used to detect these cancer cells at an incredibly sensitive level.
Manhattan Scientifics has placed one of its MRX machines at the University of Texas MD Anderson Cancer Center, which recently presented unpublished data at the World Molecular Imaging Conference in Seoul, South Korea, that showed the technology to be up to 200 times more sensitive than current imaging technologies. We believe the technology will prove far more sensitive than that. We believe the MRX technology will lead to earlier detection, fewer false positives, fewer PET and CT scans, fewer biopsies and fewer unnecessary surgeries. We believe something like this technology could be a huge cost-fighting mechanism in the battle against cancer. The collaboration with MD Anderson will generate a lot of data over the next 12–18 months, as the technology progresses through animal trials and, hopefully, moves into human clinical trials.
Additionally, the technology could be a wonderful low-cost tool to track the progression of cancer. For instance, if you’re a prostate cancer patient, you would be able to go to your physician every three to six months and see how quickly your tumor is growing, just by taking the nanoparticles and using the sensor. This could be a tremendous cost-saver. We have a $0.25/share price target on Manhattan, and it’s currently trading around $0.12/share.
TLSR: What is the regulatory pathway for this device? Will it be a 510(k) premarket notification, or will it be a premarket approval application, like a new drug application? Or do we know?
BP: We do not know at this point. But since these nanoparticles, which pass through patients like a multivitamin, are used in other medical devices, it’s not a revolutionary technology. We do not anticipate a long, onerous process. I would anticipate the 510(k).
TLSR: Will data be emanating from the human trials when they begin at MD Anderson? Will these data act as catalysts for the stock?
BP: Manhattan is a dual thesis play. Its nanotechnology platform is also being applied to structured metals. The company has a deal with Carpenter Technology Corp. (CRS:NYSE) in nanostructured titanium. The near-term catalyst for the stock is the development of this project, which should generate sufficient revenue to carry the company to its longer-term thesis, which is the development of the MRX technology.
At this point, it’s difficult to say what the timeline might be for hearing additional news. We would love to see some major guidance on when the human trials might begin next year, but again, we don’t know at this point.
TLSR: I’m noting that Senior Scientific LLC is the MRX subsidiary of Manhattan Scientifics. Is Senior Scientific a candidate for spinout?
BP: I don’t believe so. The company has not talked about that at all. Manhattan’s two businesses have a lot of interrelated pieces within nanotechnology.
Thanks Sparrow for article...
(0)
(0)